Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.LoneStar secures diabetes therapy license from University of Texas
Isoxazoles are believed to increase insulin production in human pancreas cells no longer able to produce insulin and may represent a new approach to developing treatments for both
Isoxazoles are believed to increase insulin production in human pancreas cells no longer able to produce insulin and may represent a new approach to developing treatments for both
Astex will now have no further obligation to conduct additional research work on the program. This decision follows on from the review and rationalization of Astex’s internal pipeline
Ganetespib is a non-ansamycin inhibitor of Hsp90, which is a key facilitator of cancer cell growth and survival. Ganetespib is now being studied in combination with docetaxel in
The pharmaceutical company has also adopted OneKey, the globally comprehensive healthcare professional (HCP) database, and Analyzer for dynamic reporting and actionable analytics. Cegedim’s Mobile Intelligence is believed to
According to the company, the joint solutions are expected to simplify and accelerate the use of new-genermaration mass spectrometry technologies. As per the collaboration, AB SCIEX is combining
Nobelpharma developed Fostoin in Japan. It will be marketed by Eisai and co-promoted by both companies under a previously concluded marketing agreement. Fostoin is a water-soluble prodrug of
According to the company, the restructuring will strengthen its competitive position in light of loss of Diovan patent and announces charge for Rasilez/Tekturna. The US General Medicines restructuring
The companies will end their co-development and co-promotion agreement for certolizumab pegol in Japan followed by an agreed upon transition period. UCB plans to further develop its immunology
Rotigotine Patch has been developed as a treatment for Parkinson’s disease and restless legs syndrome. The patch will provide a continuous release of the drug substance and maintains
Under the agreement Mitsubishi is responsible for any necessary development and regulatory approval costs, pay undisclosed upfront, pre-commercial milestones and pay Nuron significant royalties on commercial sales in